Evidence map›Paper›PMID 24082557›Full record

ArticleJournal of obstetrics and gynaecology of India2012

Metformin and pioglitazone in polycystic ovarian syndrome: a comparative study.

Shah Sangeeta

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Journal of obstetrics and gynaecology of India, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05952349 phase2completednot on this mapstarted 2023, after this paper: background citation

Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.

TypeinterventionalSponsorKhyber Medical University PeshawarRan2023 to 2024Enrolled88ConditionsPCOArmsOLIVE OIL 5ML/5MG (BD) NUTRITIONAL SACHET 2100MG (BD), Metformin (1000 mg Twice a day)
NCT07472179 nacompletednot on this mapstarted 2024, after this paper: background citation

Effect of Pioglitazone on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS in Comparison to Metformin

TypeinterventionalSponsorMst.Sumyara KhatunRan2024 to 2026Enrolled60ConditionsPCOS(Insulin Resistant)ArmsPioglitazone 30 Mg Oral Tablet, metformin 500 mg thrice daily
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. THBS1: a biomarker for PCOS and its role in pathogenesis via the PI3K/AKT signaling pathway.Mammalian genome : official journal of the International Mammalian Genome Society · 2026
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Administration of Cinnamon andJournal of human reproductive sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Shah SangeetaDepartment of Obstetrics & Gynecology, Gandhi Medical College, Secunderabad, 21-7-634, Chelapura, Secunderabad, Hyderabad-2, Andhra Pradesh India.
Gandhi Medical College & Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the effect of metformin and pioglitazone on insulin resistance, ovulation and hyperandrogenism in women with PCOS.

methods100 patients of age 18-30 years were included in this randomised double blind trial for treatment with either metformin or pioglitazone for a period of 6 months.

resultsAdministration of metformin and pioglitazone for 6 months revealed that 50 % of the patients achieved menstrual cyclicity. A decline in F-G grading for hirsutism within the both the groups was observed. The lipid profile also showed a decrease in total cholesterol, an increase in HDL-C, a decrease in VLDL-C levels but more so in the pioglitazone group. HOMA-IR declined more than 50-55 % with pioglitazone and 15 % with metformin. Thus, pioglitazone may be a better treatment option as far as protection from tendency to development of diabetes is conscerned. The rise in serum SHBG levels and decline in free androgen index and L/H ratio are more remarkable with pioglitazone (P < 0.05). Ovulation was restored in 44.2 and 56 % of patients on metformin and pioglitazone, respectively.

conclusionPioglitazone may be a new alternative for use in women with PCOS, providing more metabolic and reproductive benefits and possibly protection from developing diabetes and cardiovascular problem.

Indexed as

HyperandrogenismInsulin resistanceOvulationPioglitazone metforminPolycystic ovarian disease

Identifiers

PMID24082557
PMCPMC3526710
OpenAlexW1979769331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.